60
Participants
Start Date
August 1, 2024
Primary Completion Date
December 1, 2027
Study Completion Date
July 1, 2028
RP2
Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.
Bevacizumab
Anti-VEGF therapy.
Atezolizumab
Anti-PD-L1 monoclonal antibody.
Durvalumab
Anti-PD-L1 monoclonal antibody
RECRUITING
Montefiore Medical CenterMontefiore Medical Park, The Bronx
RECRUITING
Roswell Park Comprehensive Cancer Center, Buffalo
RECRUITING
UPMC Hillman Cancer Center, Pittsburgh
RECRUITING
University of Pennsylvania, Abramson Cancer Center, Philadelphia
RECRUITING
University of Maryland Medical Center, Baltimore
RECRUITING
Sylvester Comprehensive Cancer Center (University of Miami Hospital and Clinics), Miami
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
University of Tennessee Medical Center, Knoxville
RECRUITING
The West Clinic, Germantown
RECRUITING
University of Louisville, Louisville
RECRUITING
Beverly Hills Cancer Center, Beverly Hills
RECRUITING
UC San Diego Moores Cancer Center, La Jolla
Replimune Inc.
INDUSTRY